Aclarion Inc (ACONW) News

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the...

Atossa to Present at the Sidoti Small-Cap Investor Conference

SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the...

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the...

Form EFFECT - Notice of Effectiveness

Form DEF 14A - Other definitive proxy statements

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the...

Form DEL AM - Delaying amendment

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating...

Form ARS - Annual Report to Security Holders

Form PRE 14A - Other preliminary proxy statements

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the...

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the...